Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Oct 25, 2026
TickeronGET DAILY SIGNALS
Hinge Health (HNGE) Q3 Earnings Preview: Tracking +45% Revenue Growth

Hinge Health (HNGE) Q3 Earnings Preview: Tracking +45% Revenue Growth

Key Takeaways

  • Hinge Health is set to report its third-quarter 2026 results (ended September 30, 2026) after the market close on Monday, November 2, 2026.
  • Wall Street consensus calls for roughly $225 million in quarterly revenue and non-GAAP earnings of about $0.58 per share.
  • The company guided third-quarter revenue to $223 million to $225 million, pointing to roughly 45% year-over-year growth at the midpoint.
  • In its prior report, Hinge Health delivered $212.8 million in revenue (up 53% year over year) and $0.59 in non-GAAP earnings per share.
  • Management lifted full-year 2026 revenue guidance to $856 million to $860 million, reflecting about 46% growth at the midpoint.
  • The stock trades near its 52-week high, with analysts holding a consensus Buy rating and an average price target near $113.

Earnings Context and Why It Matters

Hinge Health operates as a digital healthcare provider specializing in musculoskeletal (MSK) care through software and AI-powered programs aimed at self-insured employers and health plans. It stands out in the digital-health space by combining rapid revenue expansion with a clear shift toward profitability. Heading into this report, the company has repeatedly met or exceeded its guidance while widening operating margins and producing solid free cash flow. For investors, the third-quarter update offers a key checkpoint on whether that momentum holds through the second half of 2026, particularly with the pending Cylinder Health acquisition and the push into new areas such as migraine treatment.

Earnings Expectations

Analysts project revenue of approximately $224.8 million for the third quarter of 2026, representing roughly 46% growth from the $154.2 million recorded a year earlier. The consensus non-GAAP earnings per share estimate stands near $0.58. Management’s guidance calls for revenue between $223 million and $225 million, which implies about 45% year-over-year growth at the midpoint, while the full-year 2026 outlook was raised to $856 million to $860 million.

The company brings a solid track record into this release. Second-quarter revenue reached $212.8 million, up 53% year over year and ahead of guidance, with non-GAAP operating income rising sharply and free cash flow hitting $99.6 million. Second-quarter non-GAAP EPS of $0.59 came in slightly below the roughly $0.62 consensus, showing that even a strong top-line result can miss on profitability metrics. I’m watching closely to see whether Hinge Health can again top its revenue guide and whether operating margins and cash flow continue to improve alongside the acquisition and multi-product expansion. I also checked this using Tickeron’s AI Screener to compare the stock with peers in the sector.

Market Reaction and Investor Sentiment

Sentiment ahead of the report remains broadly positive. Hinge Health shares have risen sharply since the May 2025 IPO and now trade near the upper end of their 52-week range, with a market capitalization of roughly $9 billion. Analyst actions have stayed constructive, with several firms lifting price targets and keeping Buy or Overweight ratings in the lead-up to the print.

This optimism also sets a high bar. Trading at a premium valuation, the market appears to have priced in continued strong execution, so a result that merely meets expectations may not satisfy investors. Key risks include the pace of revenue slowdown in the second half, the timing and integration of the Cylinder Health acquisition, and any pressure on margins or cash flow as the company scales newer product lines beyond its core musculoskeletal focus.

Forward Outlook and Key Factors to Monitor

Beyond the third quarter, the main question is whether Hinge Health can maintain high growth while protecting its expanding profitability. The guided path suggests a gradual slowdown from the 53% growth seen in the second quarter, which management has described as a natural comparison against a stronger second half of 2025. Investors will be looking for whether the company raises its full-year outlook again, as it has done several times over the past year.

A few elements stand out for attention. First, the integration of Cylinder Health, acquired for $105 million in cash as a virtual-first digestive-care provider, adds strategic breadth but is expected to add only modest revenue in 2026. Second, the launch of newer programs such as the migraine offering could influence the growth story into 2027. Third, operating leverage and free cash flow remain important proof points for the profitability narrative that has distinguished Hinge Health from less profitable digital-health peers. From what I see, valuation will stay a central theme given the premium multiple to sales, and the stock’s reaction will likely depend on whether management continues to deliver beats and upward revisions rather than simply matching expectations.

Using Tickeron Tools in My Research

In my own workflow, I find Tickeron’s AI Screener helpful for quickly scanning healthcare technology names and spotting patterns around earnings events like this one. It lets me apply filters for fundamentals, technical signals, and industry trends in one place, which saves time when preparing for reports like Hinge Health’s. I typically run a quick screen on comparable companies to see how the setup looks relative to the broader group before the print.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: HNGE

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


HNGE in downward trend: price dove below 50-day moving average on November 20, 2026

HNGE moved below its 50-day moving average on November 20, 2026 date and that indicates a change from an upward trend to a downward trend. In 7 of 7 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for HNGE moved out of overbought territory on November 11, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 8 similar instances where the indicator moved out of overbought territory. In 2 of the 8 cases, the stock moved lower in the following days. This puts the odds of a move lower at 25%.

The Momentum Indicator moved below the 0 level on November 17, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on HNGE as a result. In 23 of 28 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 82%.

The Moving Average Convergence Divergence Histogram (MACD) for HNGE turned negative on November 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 12 similar instances when the indicator turned negative. In 9 of the 12 cases the stock turned lower in the days that followed. This puts the odds of success at 75%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where HNGE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 69%.

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

Following a +6.45% 3-day Advance, the price is estimated to grow further. Considering data from situations where HNGE advanced for three days, in 82 of 96 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.

HNGE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 75 of 84 cases where HNGE Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 89%.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 25 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. HNGE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 68 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: HNGE's P/B Ratio (27.129) is slightly higher than the industry average of (4.523). P/E Ratio (14.015) is within average values for comparable stocks, (12.601). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.536). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (10.504) is also within normal values, averaging (6.105).

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HNGE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 98, placing this stock worse than average.

Notable companies

The most notable companies in this group are Teladoc Health (NYSE:TDOC).

Industry description

This industry comprises companies that provide services, such as equipment sterilization, research, physician management systems and consulting, that support the healthcare/medical industry. Examples of such companies include Laboratory Corporation of America Holdings, which operates one of the largest clinical laboratory networks in the world; Quest Diagnostics Inc., which is a clinical laboratory; and Syneos Health, which is a major clinical research organization.

Market Cap

The average market capitalization across the Services to the Health Industry Industry is 3.31B. The market cap for tickers in the group ranges from 708 to 49.18B. VEEV holds the highest valuation in this group at 49.18B. The lowest valued company is OTRKQ at 708.

High and low price notable news

The average weekly price growth across all stocks in the Services to the Health Industry Industry was -13%. For the same Industry, the average monthly price growth was -13%, and the average quarterly price growth was 2%. DRIO experienced the highest price growth at 5%, while LFMD experienced the biggest fall at -34%.

Volume

The average weekly volume growth across all stocks in the Services to the Health Industry Industry was 27%. For the same stocks of the Industry, the average monthly volume growth was 34% and the average quarterly volume growth was -7%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 53
Price Growth Rating: 58
SMR Rating: 86
Profit Risk Rating: 97
Seasonality Score: -5 (-100 ... +100)
Trend Prediction Engine 4
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry ServicestotheHealthIndustry

Industry
N/A
Address
455 Market Street
Phone
+1 415 726-2206
Employees
1437
Web
https://www.hingehealth.com
Interact to see
Advertisement
The ADR gapped lower in premarket trading and was at $335.71 in early regular-session trading, -4.65% from Thursday's close of $352.09. The move extends a global AI and chip unwind: investors are cutting crowded semiconductor bets on stretched valuations, rising sector debt, data-center opposition and Nvidia's leadership turmoil, and Nvidia's strong quarter failed to calm sentiment.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.
Meta Platforms fell from a $596.22 previous close to $583.40, a -2.15% move, with the decline built in premarket trading and held through early Friday action after Thursday's -3.27% drop. The drop was sector-driven, not company-specific: Anthropic slid roughly -6% to -10% premarket on its second trading day, reviving doubts that AI spending will generate returns, and AI-linked megacaps sold off broadly with Nasdaq 100 futures down about -1.5%.
ANT dropped from Thursday's record-debut close of $97.17 to about $88.56 in Friday premarket trading, a -8.86% move ahead of the opening bell, still above its $83 IPO price. The decline came from a broad AI and technology selloff rather than any Anthropic-specific disclosure: Nvidia and AMD traded lower premarket, index futures were sharply down, and renewed doubts over AI spending and valuations drove profit-taking after the +17.07% first-day gain.
IREN dropped -8.33% to $13.21 from Thursday's $14.41 close, with weakness building in premarket and extending through the first hour of regular trading. The decline extends a sector-wide neocloud rout: Anthropic's post-IPO slide and turmoil at Nvidia revived doubts about debt-funded AI data center spending, dragging CoreWeave and Nebius down with it; no IREN-specific news was released.